SEC Filing Summary for Aprea Therapeutics, Inc.

Bernd R. Seizinger, a director at Aprea Therapeutics, Inc. (APRE), reported a transaction on June 16, 2026. Seizinger acquired 3,135 shares of Common Stock and was granted 12,555 stock options. The stock acquisition, marked with transaction code "A", is related to restricted stock units that will vest on June 16, 2027, subject to continued service and potential acceleration. The stock options, also acquired under transaction code "A", have an exercise price of $0.7293 and will vest in full on June 16, 2027, contingent upon continued service and subject to acceleration. Both transactions are marked as direct ownership (D). The filing was made on June 17, 2026.